Patent · US Expired

Pyrrolotriazine kinase inhibitors

US7102002B2 · kind B2 · utility

6Cited by
6References
6Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 14, 2005
Grant dateSep 5, 2006
Priority date
Expiry dateJun 14, 2025

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P35/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides compounds of formula I,and pharmaceutically acceptable salts thereof.The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.